Benzinga | Oct 5, 2020 07:13AM EDT

Amarin Highlights Upcoming Presentation Of VASCEPA Date At European Atherosclerosis Society Oct. 4-7

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of new data at European Atherosclerosis Society (EAS) Congress 2020, being held virtually from October 4 -- October 7, 2020 that add to the growing body of knowledge on the potential mechanisms of action of VASCEPA(r) (icosapent ethyl). These new findings, based on research or analyses supported by Amarin, are being presented in one Science at a Glance presentation and one e-poster presentation by R. Preston Mason, Ph.D., President and Founder of Elucida Research LLC, and Cardiovascular Division, Department of Medicine at the Harvard Medical School-affiliated Brigham and Women's Hospital.



"The full VASCEPA story continues to unfold as we learn more about how eicosapentaenoic acid acts on a cellular level," said Craig Granowitz, M.D., Ph.D., Amarin's senior vice president and chief medical officer. "The new data presented at EAS Congress 2020 helps to further understand the unique ways by which VASCEPA lowers persistent cardiovascular risk and helps to address the global impact of cardiovascular disease."

Key data presented at EAS Congress 2020

"Eicosapentaenoic Acid, but not a Mixed Omega-3 Fatty Acid Supplement, Improved Nitric Oxide Bioavailability in Human Endothelial Cells In Vitro" -- presented on behalf of all authors by R. Preston Mason, Ph.D. -- October 5, 12:23-12:28 p.m. CEST (Central European Summer Time)

"Eicosapentaenoic Acid (EPA) Containing Phospholipids Modulate Membrane Structure" -- presented on behalf of all authors by R. Preston Mason, Ph.D. -- available from October 4

Additional information on EAS Congress 2020 can be found at https://eas2020.com/